New drug shows promise for vitiligo treatment

NCT ID NCT06113328

Terminated Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Apr 07, 2026 · Last updated May 16, 2026 · Updated 4 times

Summary

This study tested an experimental drug called MK-6194 in adults with non-segmental vitiligo, a condition that causes white patches on the skin. The goal was to see if the drug could reduce the amount of vitiligo on the face compared to a placebo, and to check its safety. The study was stopped early, but the results help researchers understand how this drug might work for vitiligo.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Amsterdam UMC, locatie AMC-Dermatology ( Site 1101)

Amsterdam, North Holland, 1105 AZ, Netherlands
Ankara Bilkent Şehir Hastanesi-Dermatology ( Site 1502)

Ankara, 06800, Turkey (Türkiye)
Burke Pharmaceutical Research ( Site 0124)

Hot Springs, Arkansas, 71913, United States
CHU de Bordeaux Hop St ANDRE ( Site 0804)

Bordeaux, Aquitaine, 33075, France
Cahaba Dermatology & Skin Health Center ( Site 0127)

Birmingham, Alabama, 35244, United States
Cantonal Hospital St.Gallen ( Site 1402)

Sankt Gallen, Canton of St. Gallen, 9007, Switzerland
Centre Hospitalier Universitaire de Nice - Hôpital l'Archet ( Site 0803)

Nice, Alpes-Maritimes, 06202, France
Centre de Recherche Dermatologique du Quebec metropolitain ( Site 0002)

Québec, Quebec, G1V 4X7, Canada
Centro Integral de Reumatología del Caribe ( Site 0405)

Barranquilla, Atlántico, 080002, Colombia
Centro Internacional de Estudios Clinicos (CIEC) ( Site 0302)

Santiago, Region M. de Santiago, 8420383, Chile
Centro de Atención e Investigación Clínica ( Site 0507)

Aguascalientes, 20129, Mexico
Centro de Investigaciones Metabólicas (CINME)-Dermatology ( Site 0203)

Buenos Aires, Buenos Aires F.D., C1027AAP, Argentina
Charité Universitaetsmedizin Berlin - Campus Mitte ( Site 0901)

Berlin, 10117, Germany
CliniSalud ( Site 0401)

Envigado, Antioquia, 055422, Colombia
Clinica Dermacross ( Site 0301)

Santiago, Region M. de Santiago, 7640881, Chile
Clinica Universidad de Navarra ( Site 1305)

Madrid, Madrid, Comunidad de, 28027, Spain
Clinical Research Chile SpA ( Site 0304)

Valdivia, Los Ríos Region, 5110683, Chile
Cryptex Investigación Clínica S.A. de C.V. ( Site 0515)

Cuauhtémoc, Ciudad de México, Mexico City, 06100, Mexico
Dawes Fretzin Clinical Research Group, LLC ( Site 0106)

Indianapolis, Indiana, 46250, United States
Dermatology Specialists of Spokane ( Site 0126)

Spokane, Washington, 99202, United States
Dermisur ( Site 0305)

Osorno, Los Lagos Region, 5310644, Chile
Diex Recherche Quebec Inc. ( Site 0008)

Québec, Quebec, G1V 4T3, Canada
Diex Recherche sherbrooke Inc. ( Site 0007)

Sherbrooke, Quebec, J1L 0H8, Canada
Enverus Medical Research ( Site 0006)

Surrey, British Columbia, V3V 0C6, Canada
Erciyes Universitesi Tıp Fakultesi Hastaneleri-Dermatology and Venereology ( Site 1506)

Kayseri, 38039, Turkey (Türkiye)
Fundación Valle del Lili ( Site 0412)

Cali, Valle del Cauca Department, 760032, Colombia
HENRI MONDOR HOSPITAL ( Site 0801)

Créteil, Val-de-Marne, 94000, France
Hacettepe Universite Hastaneleri-Dermatology ( Site 1501)

Altindağ, Ankara, 06230, Turkey (Türkiye)
Hamzavi Dermatology - Canton ( Site 0101)

Canton, Michigan, 48187, United States
Healthy Medical Center S.A.S ( Site 0403)

Zipaquirá, Cundinamarca, 250252, Colombia
Hospital Aleman-Dermatologia ( Site 0209)

Buenos Aires, C1118AAT, Argentina
Hospital Universitari de Bellvitge-Dermatology ( Site 1307)

L'Hospitalet de Llobregat, Barcelona, 08907, Spain
Hospital Universitario Puerta del Mar ( Site 1302)

Cadiz, Andalusia, 11009, Spain
Hôpital Edouard Herriot ( Site 0802)

Lyon, Auvergne-Rhône-Alpes, 69003, France
IPS SURA San Diego ( Site 0408)

Medellín, Antioquia, 50016, Colombia
Indiana University Health University Hospital-Indiana University School of Medicine, Department of (

Indianapolis, Indiana, 46202, United States
Inha University Hospital ( Site 1992)

Incheon, 22332, South Korea
Instituto Medico Strusberg ( Site 0208)

Córdoba, Córdoba Province, X5000EDC, Argentina
International Clinical Research - Tennessee LLC ( Site 0120)

Murfreesboro, Tennessee, 37130, United States
Medical University of South Carolina-Dermatology Research ( Site 0114)

Charleston, South Carolina, 29425, United States
Metro Boston Clinical Partners ( Site 0110)

Brighton, Massachusetts, 02135, United States
Nagoya City University Hospital-Dermatology ( Site 2002)

Nagoya, Aichi-ken, 467-8602, Japan
New Cross Hospital ( Site 1601)

Wolverhampton, WV10 0QP, United Kingdom
Osaka University Hospital ( Site 2004)

Suita, Osaka, 565-0871, Japan
Paratus Clinical Research Woden ( Site 1703)

Phillip, Australian Capital Territory, 2606, Australia
Pontificia Universidad Catolica de Chile-CICUC ( Site 0308)

Santiago, Region M. de Santiago, 8330034, Chile
Progressive Clinical Research ( Site 0108)

San Antonio, Texas, 78213, United States
Psoriahue ( Site 0205)

Ciudad Autonoma de Buenos Aires, Buenos Aires, C1425DKG, Argentina
Queen Elizabeth Hospital Birmingham ( Site 1603)

Birmingham, Warwickshire, B15 2TH, United Kingdom
Rambam Health Care Campus-Dermatology ( Site 1002)

Haifa, 3109601, Israel
Remington Davis Clinical Research-Outpatient ( Site 0104)

Columbus, Ohio, 43215, United States
Royal London Hospital-Dermatology Research Unit ( Site 1605)

London, England, E1 1BB, United Kingdom
Seoul National University Hospital-Dermatology ( Site 1991)

Seoul, 03080, South Korea
Severance Hospital, Yonsei University Health System-Department of Dermatology ( Site 1993)

Seoul, 03722, South Korea
Sheba Medical Center-Dermatology ( Site 1001)

Ramat Gan, 5265601, Israel
Sinclair Dermatology ( Site 1704)

Melbourne, Victoria, 3002, Australia
Skin Health Institute Inc.-Trials ( Site 1702)

Carlton, Victoria, 3053, Australia
Stat Research S.A. ( Site 0204)

Buenos Aires, Buenos Aires F.D., C1023AAB, Argentina
The Vitiligo & Pigmentation Institute of Southern California ( Site 0115)

Los Angeles, California, 90036, United States
Tokyo Medical University Hospital ( Site 2001)

Shinjuku-ku, Tokyo, 160-0023, Japan
UZ Gent ( Site 0604)

Ghent, Oost-Vlaanderen, 9000, Belgium
UZ Leuven ( Site 0601)

Leuven, Vlaams-Brabant, 3000, Belgium
Unidad biomedica avanzada monterrey-Clinical Trials ( Site 0504)

Monterrey, Nuevo León, 64460, Mexico
Universitaetsklinikum Erlangen-Hautklinik Studienambulanz ( Site 0905)

Erlangen, Bavaria, 91054, Germany
UniversitätsSpital Zürich ( Site 1401)

Zurich, Canton of Zurich, 8091, Switzerland
Universitätsklinikum Münster-Hautklinik ( Site 0904)

Münster, North Rhine-Westphalia, 48149, Germany
Virginia Clinical Research, Inc. ( Site 0109)

Norfolk, Virginia, 23502, United States
Westmead Hospital-Dermatology ( Site 1701)

Westmead, New South Wales, 2145, Australia

Conditions

Explore the condition pages connected to this study.

NON-SEGMENTAL VITILIGO NON-SEGMENTAL VITILIGO